Ann Abraham
Nurse Practitioner · Long Beach, CANPI 1447795182
Payments from drug & device makers
Across 149 payments — averaging $21.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$413
- Novo Nordisk$391
- Alkermes, Inc.$336
- Indivior Inc.$330
- Neurocrine Biosciences, Inc.$301
- Lilly USA, LLC$260
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,213100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 16 | $413 |
| Novo Nordisk | 17 | $391 |
| Alkermes, Inc. | 15 | $336 |
| Indivior Inc. | 19 | $330 |
| Neurocrine Biosciences, Inc. | 15 | $301 |
| Lilly USA, LLC | 11 | $260 |
| Braeburn Inc. | 11 | $227 |
| Teva Pharmaceuticals USA, Inc. | 9 | $183 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $131 |
| Exact Sciences | 4 | $107 |
| Amgen | 5 | $94 |
| Gilead | 4 | $92 |
| AbbVie | 4 | $83 |
| Otsuka America Pharmaceutical, Inc. | 2 | $56 |
| Vanda Pharmaceuticals Inc. | 2 | $35 |
| GSK | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 1 | $31 |
| Merck | 1 | $25 |
| Bayer | 1 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Pfizer | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
How this compares
$3,213 in reported general payments places this provider in the 90th percentile of 6,779 nurse practitioner providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 14 | $13,504 |
| Atorvastatin Calcium | 42 | $192 |
| Amlodipine Besylate | 31 | $102 |
| Omeprazole | 13 | $84 |
| Metformin Hcl | 16 | $61 |
| Ibuprofen | 16 | $60 |
| Hydrochlorothiazide | 18 | $37 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus | $391 | $13,50414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Long Beach
- Stacy Parker ByoneLong Beach$48K
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.